BLTE

Belite Bio
BLTE

$49.14

1.63%

Market Cap: 1.46B

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 20

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.42% less ownership

Funds ownership: 0.61% [Q4 2023] → 0.2% (-0.42%) [Q1 2024]

35% less funds holding

Funds holding: 17 [Q4 2023] → 11 (-6) [Q1 2024]

69% less capital invested

Capital invested by funds: $7.1M [Q4 2023] → $2.23M (-$4.87M) [Q1 2024]

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$57

16%

upside

Avg. target

$59

19%

upside

High target

$59

20%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen	20%upside $59	Buy Reiterated	13 Jun 2024
Benchmark Bruce Jackson	16%upside $57	Buy Reiterated	16 May 2024
HC Wainwright & Co. Yi Chen	20%upside $59	Buy Reiterated	15 May 2024
HC Wainwright & Co. Yi Chen	20%upside $59	Buy Maintained	22 Mar 2024
HC Wainwright & Co. Yi Chen	20%upside $59	Buy Reiterated	13 Mar 2024

See Analyst Rankings

Financial journalist opinion

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces that its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan (MHLW) for the treatment of STGD1.

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio, Inc. (NASDAQ:BLTE ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Basma Radwan - Leerink Partners Operator Hello, and thank you for joining us to discuss Belite Bio's First Quarter 2024 Financial Results.

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET on May 21, 2024.

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2024 and provided a general business update.

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference being held in New York, NY, on May 20, 2024. The Company will host a fireside chat at 3:30 pm ET.

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the first quarter ended March 31, 2024.

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a Key Opinion Leader Webinar hosted by Jennifer Kim, Director, Equity Research, of Cantor Fitzgerald on Monday, May 13, 2024, at 2:00 p.m.

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced additional findings from the 24-month Phase 2 study of Tinlarebant in adolescent Stargardt disease (STGD1) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Belite Bio Announces $25 Million Registered Direct Offering

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company (“ADSs”), each ADS representing one ordinary share of the Company at a purchase price of $38.38 per ADS, and the warrants to purchase up to an aggregate of 651,380 ADSs, which will have an initial exercise price equal to $44.14 per ADS and will be immediately exercisable and expire on the five-year anniversary of the issuance, in a registered direct offering. The closing of the offering is expected to occur on or about April 30, 2024, subject to the satisfaction of customary closing conditions.

Belite Bio Announces $25 Million Registered Direct Offering

See News Rankings